PW178 Hypertensive Women Over 50 Years Of Age: The Value Of Preoperative Electrocardiogram

Abstract

O ST E R A B ST R A C T S BP-lowering and equal or superior to other agents in reducing stroke and myocardial infarction (MI). Objectives: To review the cost and cost effectiveness of amlodipine for the treatment of hypertension. Methods: A literature review of English language articles published between 1996 and 2011 that reported economic data. The literature included health economic assessments as well as prospective and retrospective observational studies. Overall, 39 articles were reviewed and included in this study. Results: In Europe and the US, amlodipine use resulted in improved clinical outcomes (stroke and MI) at a slightly lower cost versus usual care (ARBs, angiotensin-converting enzyme inhibitors, diuretics or beta-blockers), and patients on amlodipine needed fewer hospitalizations and revascularizations at a small incremental cost. According to a 3-year Markov model of the Swiss healthcare system, an amlodipine regimen was costsaving versus an atenolol regimen. US patients switched from nifedipine GITS to amlodipine (5 or 10 mg daily) achieved significantly better BP control at an annual cost saving in favor of amlodipine of US $47,844. Total medication costs to achieve BP goal were $0.87/day on amlodipine versus $1.79/day on felodipine (with 87 and 33% achieving BP goal, respectively). Studies from other regions showed less need for hospitalizations and coronary procedures with amlodipine versus placebo and confirmed the cost-benefit of amlodipine, with the estimated costs of not using amlodipine being $6,519 in Canada (US $4,405) and 64,292 kroner in Norway (US $7,337) over a 4-month period. Conclusion: Data from the literature suggest that amlodipine is cost-effective according to the WHO-recommended threshold, and potentially cost-saving in certain settings in various countries. Disclosure of Interest: D. Liew Grant/research support from: Pfizer Inc., Consultancy for: Pfizer Inc., Honorarium from: Pfizer Inc., L. Liu Employee from: Pfizer Inc., B. Jeffers Employee from: Pfizer Inc., J. Foody Grant/research support from: Pfizer Inc., Consultancy for: Pfizer Inc.